Scinai Immunotherapeutics Ltd.

The company operates exclusively as a clinical-stage entity with no commercial sales, directing all financial activity toward research and development of its lead ADC programs and general administrative overheads. Its primary asset is the intellectual property portfolio related to novel antibody-drug conjugate technologies designed for solid tumor indications. All reported expenses are categorized under operating costs including R&D spend of $5.8M and general and administrative fees of $1.5M.

The company reports a net loss of $5.8M and negative operating profit of $11.1M, indicating heavy burn rates that threaten liquidity without new funding or sales. With total liabilities exceeding assets by over $1.7M and a retained earnings deficit of $115.8M, solvency is a critical concern if clinical trials fail or financing markets tighten. The absence of revenue means the stock value is entirely speculative based on future clinical success probabilities rather than current cash flows.

Proprietary antibody-drug conjugate platform technology targeting specific pathways in solid tumors offers a differentiated therapeutic approach compared to standard-of-care therapies. Strategic partnerships or licensing arrangements could provide near-term revenue streams if the company secures collaborations with larger biopharma entities, though none are currently reflected in revenue. The potential for high-value approvals in the oncology space provides significant upside value upon successful clinical progression.